Premium
Controlling Nutritional Status score does not predict patients' overall survival or hepatocellular carcinoma recurrence after deceased donor liver transplantation
Author(s) -
Pravisani Riccardo,
Mocchegiani Federico,
Isola Miriam,
Lorenzin Dario,
Adani Gian Luigi,
Cherchi Vittorio,
Righi Elda,
Terrosu Giovanni,
Vivarelli Marco,
Risaliti Andrea,
Baccarani Umberto
Publication year - 2020
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13786
Subject(s) - medicine , hepatocellular carcinoma , hazard ratio , interquartile range , milan criteria , liver transplantation , gastroenterology , cumulative incidence , retrospective cohort study , multivariate analysis , incidence (geometry) , transplantation , carcinoma , proportional hazards model , confidence interval , oncology , surgery , physics , optics
Abstract Background The Controlling Nutritional Status (CONUT) score is a newly developed laboratory‐derived immunonutritional score which has been validated as prognostic marker for survival and tumor recurrence in surgically treated patients with various tumor types, including hepatocellular carcinoma (HCC). The aim of the present study was to test the CONUT score performance in HCC patients treated with liver transplantation (LT). Methods A retrospective study on a bi‐centers cohort of 280 HCC patients submitted to LT between 2006 and 2017 was performed. Indication to LT was limited to Milan criteria or UCSF criteria, defined by preoperative imaging. Results Median pre‐LT CONUT score was 5 (interquartile range 3‐7). Overall patients' survival at 1, 3, and 5 years was 84%, 76.6%, and 68.3%, respectively. Multivariate analysis showed that HCC recurrence (hazard ratio [HR] = 1.987, P = .012] and pre‐LT neutrophil to lymphocyte ratio (NLR) (HR = 1.064, P = .003) were independent risk factors for reduced survival. Cumulative incidence of HCC recurrence at 1, 3, and 5 years was 5.1%, 11.5%, and 15.5%, respectively. Pre‐LT platelet‐to‐lymphocyte ratio (PLR) (subdistribution hazard ratio [SHR] = 1.086, P = .044], tumor max diameter (SHR = 1.695, P < .001), and bilobar tumor distribution (SHR = 6.892, P = .006) were independent risk factors for tumor recurrence. The CONUT score did not show any prognostic value. Conclusions The CONUT score did not predict poor survival or tumor recurrence in LT recipients.